Aug 21 2026 02:53 AM EST
Twist Bioscience Raises Guidance as AI-Driven Demand and Operational Gains Reshape Market Outlook
Shares of Twist Bioscience Corporation (NASDAQ: TWST) have climbed 132% in the past three months, propelled by raised revenue guidance, robust execution in AI-enabled drug discovery, and sustained improvement in gross margins. The company’s record quarterly sales and strengthened capital position have prompted a broad market reassessment of its growth prospects, though persistent losses and sector risks temper the outlook.
KEY FIGURES
- Q3 FY2026 revenue $118.4 million, up 23% year-over-year
- Gross margin reached 52.8%, a 120 bps sequential improvement
- Net loss for Q3 $35.1 million (EPS loss $0.56)
- FY2026 revenue guidance raised to $456–$457 million
- Cash and investments at quarter-end $166.8 million, before $300 million equity raise in August
- Market capitalization $8.9 billion (August 19, 2026)
Guidance Hike and AI Momentum Drive Rerating
Twist’s latest rally follows its August 2026 decision to raise full-year revenue guidance to $456–$457 million, reflecting around 21% annual growth. The move, paired with stronger-than-expected Q3 revenue of $118.4 million and a sequential gross margin improvement to 52.8%, reinforced market confidence in the company’s ability to capitalize on accelerating demand for synthetic DNA products in AI-driven drug discovery and next-generation sequencing.
The August 18 announcement of successful AI-designed protein validation, leveraging Anthropic’s Claude AI models, added to the momentum, with shares rising more than 22% in a single day and reaching a 52-week high of $141. Analysts at TD Cowen and Baird subsequently raised their price targets to $115, citing Twist’s execution and the expanding commercial opportunity in AI-enabled workflows.
Operational Improvements and Product Innovation
The company’s results were underpinned by operational gains, with manufacturing costs reduced by 60% and turnaround times shortened by 73% over three years. The launch of complex genes, rapid delivery of over 1,800 constructs during early access, and new next-generation sequencing kits have supported customer adoption and margin expansion.
Segment results highlight broad-based demand: DNA synthesis and protein solutions revenue rose 39% year-over-year to $56.6 million in Q3, while NGS applications contributed $61.8 million (+12% YoY) and therapeutics revenue increased 49% to $40.4 million. Geographic growth was led by the Americas (+30% YoY), with APAC (+26%) and EMEA (+9%) also contributing.
AI-Enabled Drug Discovery and Market Position
Twist is emerging as a key infrastructure provider for the integration of AI in biology, with management forecasting triple-digit percentage growth in AI-related orders for both fiscal 2026 and 2027. The company’s silicon-based DNA synthesis platform, supported by more than 700 patents and proprietary automation, enables high-throughput production at a scale and cost advantage over competitors such as GenScript, IDT, Thermo Fisher, and Eurofins.
The company’s addressable market is projected to reach $13 billion by 2030, with secular growth drivers including the expansion of genomics, molecular diagnostics, and synthetic biology. Over 3,500 customers and a diversified revenue base—no single customer represents more than 10% of sales—add resilience to the growth profile.
Capital Markets and Profitability Path
Twist’s capital base was bolstered by a $300 million public equity raise in August at $96 per share, as well as a $200 million at-the-market facility. The company reiterated its target for adjusted EBITDA breakeven in Q4 2026, with management aiming for gross margins above 60% as scale and operating leverage improve.
Despite these improvements, Twist remains loss-making, reporting a Q3 net loss of $35.1 million and trailing-twelve-month net income of -$136.7 million. Free cash flow remains negative, and consensus does not forecast GAAP profitability for at least three years.
INVESTOR WATCHLIST
- Persistent net losses and negative free cash flow, with profitability dependent on sustained revenue growth and margin expansion
- Significant insider selling in recent months, including CEO and COO transactions, though attributed to tax and vesting events
- Competitive risks from ongoing innovation in DNA synthesis and price pressure, particularly from enzymatic synthesis technologies
- Potential regulatory and geopolitical headwinds, including biosecurity, US-China trade tensions, and evolving compliance requirements
- High valuation multiples (Price/Sales around 20x), with share price volatility above market averages
Twist’s strong three-month share-price performance reflects a repricing of the company’s growth outlook, driven by evidence of operational execution, expanding AI-related demand, and improving financial metrics. The company’s raised guidance and path to adjusted EBITDA breakeven have reinforced institutional and analyst confidence, though risks around profitability, dilution, competition, and sector volatility remain central to the investment debate. Whether these gains can be sustained will depend on Twist’s ability to deliver continued top-line growth, margin improvement, and execution on its strategic roadmap in a dynamic and highly competitive industry.